Evidence map›Paper›PMID 38858590›Full record

ArticleOncogene2024

MLK3 promotes prooncogenic signaling in hepatocellular carcinoma via TGFβ pathway.

Rong Ke, Navin Viswakarma, Mary Menhart, Sunil Kumar Singh, Sandeep Kumar, Piush Srivastava, Kanchan Vishnoi, Tanushree Kashyap, Deepti Srivastava, Rakesh Sathish Nair and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rong KeDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Navin ViswakarmaDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Mary MenhartDepartment of Pharmacology & Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Sunil Kumar SinghDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, 60612, USA.ORCID 0000-0001-7639-9212
Sandeep KumarDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, 60612, USA.ORCID 0000-0002-2376-6469
Piush SrivastavaDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, 60612, USA.ORCID 0000-0003-4646-9392
Kanchan VishnoiDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Tanushree KashyapDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Deepti SrivastavaDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Rakesh Sathish NairDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, 60612, USA.ORCID 0000-0002-0174-5472
Mark Maienschein-ClineResearch Informatics Core, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Xiaowei WangDepartment of Pharmacology & Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Ajay RanaDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, 60612, USA.ORCID 0000-0003-0951-2566
Basabi RanaDepartment of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, 60612, USA. basrana@uic.edu.ORCID 0000-0001-8843-2833

Funding

Developing Nano Technology for HER2 Directed TherapyR01CA216410 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LI, SONG, RANA, AJAY NMN · 2017 to 2021
$2.8M
Mechanistic Insight on the Role of Berberine and AMPK in Hepatocellular CarcinomaR03CA219764 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RANA, BASABI · 2019 to 2020
$160k
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA216410U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA219764U.S. Department of Veterans Affairs (Department of Veterans Affairs) BX003296U.S. Department of Veterans Affairs (Department of Veterans Affairs) BX004855U.S. Department of Veterans Affairs (Department of Veterans Affairs) BX004903U.S. Department of Veterans Affairs (Department of Veterans Affairs) BX005791
6 · The paper itself

Abstract

Advanced hepatocellular carcinoma (HCC) is a lethal disease, with limited therapeutic options. Mixed Lineage Kinase 3 (MLK3) is a key regulator of liver diseases, although its role in HCC remains unclear. Analysis of TCGA databases suggested elevated MAP3K11 (MLK3 gene) expression, and TMA studies showed higher MLK3 activation in human HCCs. To understand MLK3's role in HCC, we utlized carcinogen-induced HCC model and compared between wild-type and MLK3 knockout (MLK3

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMAP Kinase Kinase KinasesMitogen-Activated Protein Kinase Kinase Kinase 11Signal TransductionTransforming Growth Factor betaAnimalsCell Line, TumorCell ProliferationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMaleMiceMice, KnockoutMAP Kinase Kinase KinasesMitogen-Activated Protein Kinase Kinase Kinase 11Transforming Growth Factor beta

Identifiers

PMID38858590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.